Commitments and Contingencies (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2017 |
Jun. 30, 2016 |
Jun. 30, 2017 |
Jun. 30, 2016 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Commitments and Contingencies (Textual) | ||||||
| Rent expense | $ 56,595 | $ 40,640 | $ 111,810 | $ 75,035 | $ 171,294 | $ 107,385 |
| 2011 Exclusive Agreement [Member] | ||||||
| Commitments and Contingencies (Textual) | ||||||
| Milestone payment | $ 765,000 | |||||
| License reduced percentage | 50.00% | |||||
| Aggregate maintenance fees for first five years | $ 80,000 | |||||
| Maintenance fees annually after first five years | $ 50,000 | |||||
| Royalty percentage | 2.00% | |||||
| Minimum royalty expense | $ 75,000 | |||||
| Royalty description | The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials). | |||||
| 2013 Exclusive Agreement [Member] | ||||||
| Commitments and Contingencies (Textual) | ||||||
| Milestone payment | $ 765,000 | |||||
| License reduced percentage | 50.00% | |||||
| Aggregate maintenance fees for first three years | $ 7,500 | |||||
| Maintenance fees annually after first five years | $ 5,000 | |||||
| Royalty percentage | 2.00% | |||||
| Minimum royalty expense | $ 75,000 | |||||
| Royalty description | The Company is required to pay The Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials). | |||||
| License costs | $ 10,000 | |||||